Mednax, Inc (NYSE:MD) Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the transaction, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Mednax, Inc (NYSE MD) traded up $2.02 during midday trading on Friday, reaching $43.37. 2,080,514 shares of the company’s stock were exchanged, compared to its average volume of 1,302,315. The company has a market cap of $3.90 billion, a P/E ratio of 12.73 and a beta of 0.32.

Mednax (NYSE:MD) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.87. The company had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. Mednax’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 EPS. research analysts forecast that Mednax, Inc will post 3.08 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cesar L. Alvarez Sells 10,668 Shares of Mednax, Inc (MD) Stock” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/cesar-l-alvarez-sells-10668-shares-of-mednax-inc-md-stock.html.

MD has been the topic of several recent research reports. Robert W. Baird reiterated a “hold” rating and issued a $47.00 price target on shares of Mednax in a research report on Sunday, September 3rd. BidaskClub downgraded shares of Mednax from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective on the stock in a research report on Sunday, September 17th. Jefferies Group LLC restated a “hold” rating and set a $53.00 price objective (up from $50.00) on shares of Mednax in a research report on Thursday, July 6th. Finally, BMO Capital Markets started coverage on shares of Mednax in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. Mednax presently has an average rating of “Hold” and a consensus target price of $55.33.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its holdings in Mednax by 415.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 272,172 shares of the company’s stock valued at $11,736,000 after acquiring an additional 219,322 shares during the last quarter. FDx Advisors Inc. increased its holdings in Mednax by 55.9% in the 3rd quarter. FDx Advisors Inc. now owns 13,854 shares of the company’s stock valued at $597,000 after acquiring an additional 4,970 shares during the last quarter. Swiss National Bank increased its holdings in Mednax by 0.4% in the 3rd quarter. Swiss National Bank now owns 343,000 shares of the company’s stock valued at $14,790,000 after acquiring an additional 1,300 shares during the last quarter. IPG Investment Advisors LLC increased its holdings in Mednax by 52.6% in the 3rd quarter. IPG Investment Advisors LLC now owns 200,520 shares of the company’s stock valued at $8,646,000 after acquiring an additional 69,130 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Mednax by 0.7% in the 3rd quarter. Principal Financial Group Inc. now owns 398,057 shares of the company’s stock valued at $17,164,000 after acquiring an additional 2,665 shares during the last quarter. Institutional investors own 99.97% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.